GPX 100

Drug Profile

GPX 100

Latest Information Update: 03 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gem Pharmaceuticals
  • Class Anthracyclines; Cytostatic antibiotics
  • Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 03 Sep 2007 Discontinued - Phase-II for Cancer in USA (unspecified route)
  • 12 Feb 2004 ACCESS Oncology has been acquired by Keryx Biopharmaceuticals
  • 25 Jan 2002 GPX 100 has been licensed to ACCESS Oncology worldwide except for Asia where Gem Pharmaceuticals retains rights
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top